Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL320231 | 0.92 | TP53 (0.65) | TP53ALDH1A1LMNAOR51E2SLC22A6 | |
| Lactic Acid SCHEMBL15512248 | 0.92 | TP53 (0.65) | TP53ALDH1A1LMNAOR51E2SLC22A6 | |
| Lactic Acid SCHEMBL4527725 | 0.92 | TP53 (0.65) | TP53ALDH1A1LMNAOR51E2SLC22A6 | |
| Lactic Acid SCHEMBL18761913 | 0.90 | TP53 (0.61) | TP53ALDH1A1LMNAOR51E2SLC22A6 | |
| Lactic Acid SCHEMBL41708 | 0.89 | TP53 (0.69) | TP53OR51E2SLC22A6CYP1A2SMN1; SMN2 | |
| Lactic Acid SCHEMBL5269783 | 0.89 | TP53 (0.69) | TP53OR51E2SLC22A6CYP1A2SMN1; SMN2 | |
| Lactic Acid SCHEMBL4263083 | 0.89 | TP53 (0.69) | TP53OR51E2SLC22A6CYP1A2SMN1; SMN2 | |
| Lactic Acid SCHEMBL4261279 | 0.89 | TP53 (0.69) | TP53OR51E2SLC22A6CYP1A2SMN1; SMN2 | |
| Lactic Acid SCHEMBL419437 | 0.89 | TP53 (0.69) | TP53OR51E2SLC22A6CYP1A2SMN1; SMN2 | |
| Lactic Acid SCHEMBL3845012 | 0.89 | TP53 (0.69) | TP53OR51E2SLC22A6CYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8956644-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2015-02-17 | — | — | US | claimed |
| US-20130317456-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2013-11-28 | — | — | US | claimed |
| US-20130273139-A1 | TRANSDERMAL DELIVERY SYSTEMS | DURECT CORPORATION | 2013-10-17 | — | — | US | claimed |
| EP-2484347-A1 | Transdermal delivery systems comprising bupivacaine | Durect Corporation (US) | 2012-08-08 | — | — | EP | claimed |
| EP-2117521-B1 | TRANSDERMAL DELIVERY SYSTEMS COMPRISING BUPIVACAINE | DURECT CORP (US) | 2012-06-27 | — | — | EP | claimed |
| US-20090060986-A1 | Transdermal delivery systems | DURECT CORPORATION | 2009-03-05 | — | — | US | claimed |
| WO-2008066642-A2 | TRANSDERMAL DELIVERY SYSTEMS COMPRISING BUPIVACAINE | DURECT CORPORATION (US) | 2008-06-05 | — | — | WO | claimed |
| US-20180110739-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170007549-A1 | Transdermal Delivery Systems | DURECT CORPORATION | 2017-01-12 | — | — | US | disclosed |
| US-8956644-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130345260-A1 | High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device | DURECT CORPORATION (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130317456-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130273139-A1 | TRANSDERMAL DELIVERY SYSTEMS | DURECT CORPORATION | 2013-10-17 | — | — | US | disclosed |
| EP-1212092-B1 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | DURECT CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004052336-A2 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | DURECT CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040101557-A1 | High viscosity liquid controlled delivery system and medical or surgical device | DURECT CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-6413536-B1 | DELIVERING ACTIVE MATERIALS | SOUTHERN BIOSYSTEMS, INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1212092-A2 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | Southern Biosystems, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001015734-A2 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AND MEDICAL OR SURGICAL DEVICE | SOUTHERN BIOSYSTEMS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| US-5399353-A | Oligomers of lactic/glycolic acid | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040101557-A1 | High viscosity liquid controlled delivery system and medical or surgical device | MMP1, MMP13, MMP9 | TP53 1769/4885ALDH1A1 3877/4885LMNA 1060/4885 |
| US-20130345260-A1 | High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device | MMP1, MMP13, MMP9 | TP53 1783/4885ALDH1A1 3937/4885LMNA 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.